Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implementation study of every-2-month long-acting cabotegravir + rilpivirine in virologically suppressed adults with HIV-1
NL-OMON54940Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cabotegravir and rilpivirine in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: Change from baseline at Month 12 in implementation acceptability, appropriateness, and feasibility for study staff. Started Oct 2020; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON54940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54940.